In a report released yesterday, Justin Zelin from BTIG maintained a Buy rating on Lyra Therapeutics (LYRA – Research Report), with a price target of $15.00. The company’s shares closed last Friday at $5.24.
According to TipRanks, Zelin is a 4-star analyst with an average return of 8.3% and a 45.86% success rate. Zelin covers the Healthcare sector, focusing on stocks such as Legend Biotech, Viking Therapeutics, and 89bio.
Lyra Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $13.50.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $5.50 and a one-year low of $1.86. Currently, Lyra Therapeutics has an average volume of 192.5K.
Based on the recent corporate insider activity of 6 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of LYRA in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Lyra Therapeutics (LYRA) Company Description:
Lyra Therapeutics Inc a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat diseases. The company’s technology platform, XTreo, is designed to precisely and consistently deliver medicines directly to the affected tissue for sustained periods with a single administration.
Read More on LYRA:
